Dofetilide, a New Class III Antiarrhythmic Agent

  title={Dofetilide, a New Class III Antiarrhythmic Agent},
  author={Thomas L. Lenz and Daniel E. Hilleman},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  • T. L. Lenz, D. Hilleman
  • Published 1 July 2000
  • Medicine
  • Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Dofetilide is a new antiarrhythmic agent recently approved for conversion and maintenance of sinus rhythm in patients with atrial fibrillation (AF) and atrial flutter (AFl). It is a class III antiarrhythmic that works by selectively blocking the rapid component of the delayed rectifier outward potassium current. Dofetilide prolongs the effective refractory period in accessory pathways, both anterograde and retrograde. This can be seen on the electrocardiogram through a dose‐dependent… 
A Benefit-Risk Assessment of Class III Antiarrhythmic Agents
Subgroup analyses of trials with amiodarone and dofetilide suggest that patients with atrial fibrillation may have a mortality reduction with these drugs, however, this needs to be tested in a prospective trial.
Current Drug Treatment Strategies for Atrial Fibrillation and TASK-1 Inhibition as an Emerging Novel Therapy Option
The DOxapram Conversion TO Sinus rhythm (DOCTOS)-Trial will reveal whether doxaprams, a potent TASK-1 inhibitor, can be used for acute cardioversion of persistent and paroxysmal AF in patients, potentially leading to a new treatment option for AF.
Antiarrhythmic Agents
Knowing how antiarrhythmic agents are metabolised by the cytochrome P450 enzyme system may allow clinicians to predict potential interactions and help to optimise drug therapy for every patient.
A benefit–risk assessment of class III antiarrhythmic agents
The benefits discussed include the ability to maintain sinus rhythm in persistent atrial fibrillation patients, and reducing the need for implantable cardioverter defibrillator shock/antitachycardia therapy, since no class III antiarrhythmic agents have proven survival benefit.
Pharmacologic Therapy in Patients with Implantable Cardioverter-Defibrillators
Clearly, there are prudent and clinically indicated uses for digoxin, angiotensin converting enzyme inhibitors, diuretics, antihypertensive, β-adrenergic blockers, and antianginal agents in many of these patients; however, a discussion of their specific uses in these patients is beyond the scope of this review.
Considerations for dofetilide use in the elderly.
  • Lindsey W Crist, D. Dixon
  • Medicine
    The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists
  • 2014
An 85-year-old African-American female with atrial arrhythmias on dofetilide maintenance therapy who presented to an ambulatory cardiology clinic with hypotension was decided to discontinue chlorthalidone to avoid the potential drug interaction with do Fetilide.
Pharmacokinetics and Bioequivalence of Branded and Generic Formulations of Dofetilide 0.5‐mg Capsules After Single‐Dose Administration in Healthy Subjects
Generic dofetilide 0.5‐mg capsule pharmacokinetics were compared with branded product in 2 open‐label, 2‐way crossover, single‐dose studies — 1 study each in fasted and fed healthy subjects.
NIP-141, a multiple ion channel blocker, terminates aconitine-induced atrial fibrillation and prevents the rapid pacing-induced atrial effective refractory period shortening in dogs.
  • N. Hashimoto, T. Yamashita, N. Fujikura, N. Tsuruzoe
  • Biology, Medicine
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
  • 2007
NIP-141 terminated AF in aconitine-induced atrial fibrillation and prevented the atrial remodelling by short-term rapid pacing in dogs, possibly via the blocking of Na(+) and Ca(2+) channels.


Dofetilide, A Novel Class III Antiarrhythmic Agent
Pharmacodynamic data demonstrate dose- and concentration-dependent effects on myocardial repolarization as evidenced by prolongations of the QTC interval, supporting the contention that dofetilide is a highly selective class III antiarrhythmic agent.
Electropharmacology of dofetilide, a new class III agent, in anaesthetised dogs.
Superiority of ibutilide (a new class III agent) overdl-sotalol in converting atrial flutter and atrial fibrillation
Ibutilide (given in 1 or 2 mg doses over 10 minutes) is highly effective for rapidly terminating persistent atrial fibrillation or atrial flutter and is a potential alternative to currently available cardioversion options.
Atrial flutter can be terminated by a class III antiarrhythmic drug but not by a class IC drug.
Dofetilide is more effective than flecainide in the conversion of atrial flutter to sinus rhythm, despite the fact that flec Cainide produced a more prolonged flutter cycle length.
New class III antiarrhythmic drugs.
Initial animal and clinical studies have shown that class III agents are effective against re-entrant supraventricular and ventricular arrhythmias without having any important negative inotropic effect in the compromised ventricle.